Asahi Kasei Bioprocess
Asahi Kasei Bioprocess manufactures capital equipment to accommodate the increasing number of antisense oligonucleotides and RNAi-based drugs entering Phase II or Phase III clinical trials. By pairing Asahi Oligosynthesizers and Synthesis Columns with Cleavage and Deprotection Systems, process engineers can increase throughput and drive down costs during the synthesis process. In addition, MPLC and HPLC columns and systems feature minimized system hold-up along with sanitary or hygienic flow paths optimized for ion exchange purification of oligonucleotides and higher backpressures. Please visit at Stand 47 for more information.